Skip to main content

Moderna beats estimates but slashes guidance on low EU sales, competitive U.S. vaccine market

Moderna now expects 2024 product revenue to come in between $3 billion and $3.5 billion, down from a previous guidance of $4 billion.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.